Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Skräddarsydd plan för överlevnadsvård för att förbättra förståelsen och tillgången till överlevnadsvård hos svarta eller afroamerikanska patienter med lokaliserad eller oligometastatisk prostatacancer

29 september 2026 uppdaterad av: Viraj Master, Emory University

Ta itu med hälsokompetens med en skräddarsydd plan för överlevnadsvård för att förbättra tillgången hos underbetjänade afroamerikanska prostatacancerpatienter

This clinical trial compares the impact of a tailored survivorship care plan (SCP) to a standard SCP on the understanding of and access to survivorship care in black or African American patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread from where it first started (primary site) to a limited number of places in the body (oligometastatic). SCPs summarize treatment history and recommendations for monitoring and maintaining health, and may also include potential long term effects of treatments received. The intention of a SCP is to help patients participate in their own health care. However, many patients have below basic levels of health literacy, meaning, they have a lower ability to obtain, communicate, process and understand basic health information and services to make health decisions. In fact, poor health literacy has been linked with worse quality of life in prostate cancer survivors. A tailored SCP includes the addition of an educational supplement based on lower reading and writing skills (low literacy) and may address health literacy barriers to understanding of treatment options and side effects. A standard SCP uses a template based on the American Society of Clinical Oncology (ASCO) guidelines for prostate cancer. A tailored SCP with low literacy educational supplements may be more effective compared to a standard SCP in improving understanding and access to survivorship care in black or African American patients with localized or oligometastatic prostate cancer.

Studieöversikt

Detaljerad beskrivning

PRIMARY OBJECTIVES:

I. Compare outcomes after patients receive usual care from their providers with a standard SCP and after patients receive tailoring of the SCP with the low literacy educational supplement.

II. To quantify the potential benefit of tailoring the care plan and the educational supplement.

III. Compare providers' assessment of patients':

IIIa. Health literacy; IIIb. Comprehension of survivorship care recommendations; IIIc. Understanding of long term and late effects from treatment; IIId. To measures obtained from patients.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I (INTERVENTION): Patients receive standard SCP during a provider visit and a tailored SCP with a low literacy educational supplement during a structured interview over 30-60 minutes.

GROUP II (CONTROL): Patients receive standard SCP using the prostate cancer ASCO template during a provider visit and undergo a structured interview over 30-60 minutes.

Studietyp

Interventionell

Inskrivning (Beräknad)

150

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30322
        • Rekrytering
        • Emory University Hospital/Winship Cancer Institute
        • Kontakt:
        • Huvudutredare:
          • Viraj Master, MD, PhD, FACS
      • Atlanta, Georgia, Förenta staterna, 30303
        • Rekrytering
        • Grady Memorial Hospital
        • Kontakt:
        • Huvudutredare:
          • Viraj Master, MD, PhD, FACS
      • Atlanta, Georgia, Förenta staterna, 30329
        • Rekrytering
        • Atlanta VA Medical Center
        • Kontakt:
        • Huvudutredare:
          • Mohammad Hajiha, MD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Manlig

Beskrivning

Inclusion Criteria:

  • Black and African American men who are disease-free after completing primary surgery and/or radiation treatment for localized or oligometastatic prostate cancer between 1 to 4 years prior to enrollment. (Race/ethnicity per medical records and self report)
  • Patients who are still receiving adjuvant androgen deprivation therapy following primary radiation with non-palliative intent may be included

Exclusion Criteria:

  • Dementia or cognitive impairment per provider clinical assessment
  • Unable to give informed consent in the judgement of the patient's oncology provider
  • Recurrent prostate cancer after primary treatment
  • Less than 18 years of age at the time of informed consent
  • Diagnosis of active second malignancy requiring treatment
  • Individuals who are not able to clearly understand English since the outcome measures require understanding of English

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Stödjande vård
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Group I (standard SCP, tailored SCP)

Patients receive standard SCP during a provider visit and a tailored SCP with a low literacy educational supplement during a structured interview over 30-60 minutes.

Ancillary studies

Receive a low literacy educational supplement

Andra namn:
  • Utbildning för intervention
  • Intervention by Education
  • Intervention genom utbildning
  • Intervention, utbildning

Undergo a structured interview

Receive standard SCP

Andra namn:
  • Stödjande terapi
  • Symtomhantering
  • Terapi, stödjande

Receive a tailored SCP

Andra namn:
  • Stödjande terapi
  • Symtomhantering
  • Terapi, stödjande
Aktiv komparator: Group II (standard SCP)

Patients receive standard SCP using the prostate cancer ASCO template during a provider visit and undergo a structured interview over 30-60 minutes.

Ancillary studies

Undergo a structured interview

Receive standard SCP

Andra namn:
  • Stödjande terapi
  • Symtomhantering
  • Terapi, stödjande

Receive a tailored SCP

Andra namn:
  • Stödjande terapi
  • Symtomhantering
  • Terapi, stödjande

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Comprehension of survivorship care recommendations and prostate specific antigen surveillance
Tidsram: At baseline and up to 3 month phone call

Comprehension will be scored as dichotomous variables, correct or incorrect. The proportion of patients who correctly understand after the standard survivorship care plan (SCP) compared to the proportion who correctly understand after the standard SCP + tailoring + educational support will be analyzed using a two-tailed Z-score test for equality of two proportions at a significance level of P < 0.05.

At baseline and up to 3 month phone call
Comprehension of treatment side effects and late effects
Tidsram: At baseline and up to 3 month phone call

Comprehension will be scored as dichotomous variables, correct or incorrect. The proportion of patients who correctly understand after the standard SCP compared to the proportion who correctly understand after the standard SCP + tailoring + educational support will be analyzed using a two-tailed Z-score test for equality of two proportions at a significance level of P < 0.05.

At baseline and up to 3 month phone call

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Access to survivorship care for late and long-term side effects
Tidsram: At baseline and up to 3 month phone call

Will be assessed using the Patients Access Score (PAS). Descriptive statistics will be used to characterize patient access to survivorship care. The difference in mean PAS will be compared between the two arms using a 2 sample t-test. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Linear regression models will be used to identify predictors of access to survivorship care. Parsimonious models will be favored due to the relatively small sample size.

At baseline and up to 3 month phone call
Decision regret
Tidsram: At baseline and up to 3 month phone call

Descriptive statistics will be used to characterize decision regret. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size.

At baseline and up to 3 month phone call
Change in decisional conflict
Tidsram: At baseline and up to 3 month phone call

The two-sample t-test will be used to evaluate the change in the average decisional conflict score between patients in the control arm (standard SCP) and patients in the intervention arm (standard SCP + tailoring + educational supplement).

At baseline and up to 3 month phone call
Preparedness for survivorship
Tidsram: At baseline and up to 3 month phone call

Descriptive statistics will be used to characterize preparedness for survivorship. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size.

At baseline and up to 3 month phone call
Patient self-efficacy
Tidsram: At baseline and up to 3 month phone call

Descriptive statistics will be used to characterize patient self-efficacy. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size.

At baseline and up to 3 month phone call

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Viraj Master, MD, PhD, FACS, Emory University Hospital/Winship Cancer Institute

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

7 november 2025

Primärt slutförande (Beräknad)

31 december 2029

Avslutad studie (Beräknad)

31 december 2030

Studieregistreringsdatum

Först inskickad

4 november 2024

Först inskickad som uppfyllde QC-kriterierna

4 november 2024

Första postat (Faktisk)

5 november 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

30 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

29 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera